Skip to main content
OpenTrials
Recruiting

NCT Number: NCT00018889

Phenotype/Genotype Correlations in Movement Disorders

The goal of this protocol is to identify families with inherited movement disorders and evaluate disease manifestations to establish an accurate clinical diagnosis by using newest technological advances and investigate the underlying molecular mechanisms. Studies of inherited movement disorders in large families with good genealogical records are especially valuable. Patients with diseases of known molecular basis will be genotyped in order to investigate phenotype/genotype correlation. Patients with disease of unknown or incomplete genetic characterization will be studied with a hope of contributing to the identification of specific disease-causing genes and genetic mechanisms responsible for a specific disorder.

Recruiting

Interested in participating?

Request Info

Key information

Age range

2 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

Location status: Recruiting

Location contact

For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

CONTACT

[email protected]

800-411-1222 ext. TTY dial 711

About this study

Objective: The primary objective of this study is to perform phenotypic and genotypic characterizations of patients and family members with a known or suspected diagnosis of a movement disorder and screen for eligibility to participate in other movement disorder related protocols:

  • 14-N-0086 Deep brain stimulation therapy in movement disorders
  • 11-N-0211 Deep brain stimulation surgery for movement disorders
  • 000865: Natural history of movement disorders
  • 00-N-0043: Clinical and molecular manifestations of inherited neurologic disorders
  • 03-AG-N-329 (NIA): The genetic characterization of movement disorders and dementias
  • 20M0082 Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease; Institute (NIMH)

The secondary goals of this protocol are to learn more about genetic causes of movement disorders and their phenotypic associations; identify patients and families with inherited movement disorders; evaluate disease manifestations to establish an accurate clinical diagnosis; and to investigate the underlying molecular mechanisms. Studies of inherited movement disorders in large families with well-documented genealogical records are especially valuable. The study will also assess a series of exploratory peripheral biomarkers, including, but not limited to, those delineated by DNA, RNA, protein, and/or metabolite alterations in an effort to more accurately predict those with, or at risk of having, the specific neurological disease.

Study population: Subjects older than 2 years old with movement disorders and their family members will be enrolled. Patients with diseases of known molecular basis will be genotyped in order to investigate phenotype/genotype correlations. Patients with disease of unknown or incomplete genetic characterization will be studied with a hope of contributing to the identification of specific disease-causing genes and genetic mechanisms and/or peripheral bio-signatures involved in a particular disorder.

Design:

This is an observational diagnostic study of movement disorders and their progression and pathophysiology.

Outcome measures: Determination of phenotype/genotype correlations in specific movement disorders, referral of patients and/or family members for participation in other NIH studies, gene identification if not known, gene expression and protein, metabolite and nucleic acid levels, collection of blood cells and generation of induced pluripotent stem cell lines, and establishment of a clinical diagnosis when possible.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

  • INCLUSION CRITERIA:
  • Individuals with suspected movement disorders
  • Family members of movement disorders patients
  • Ability to give informed consent or have a legally authorized representative able to give consent (for adults without consent capacity) or parent/guardian able to provide informed consent (for a child)
  • If unable to give informed consent, ability to give assent (for children or adults without consent capacity)
  • NIH Employees can participate in this study if they meet eligibility.

Exclusion criteria

  • Pregnant women
  • Children less than 2 years of age
  • Employees of the Parkinson's Disease Clinic, NINDS

Exclusion criteria

for MRI

  • Presence of metal in subject s body which would make having an MRI scan unsafe, such as pacemakers, stimulators, pumps, aneurysm clips, metallic prostheses, artificial heart valves, cochlear implants or shrapnel fragments, or if subject was a welder or metal worker, since small metal fragments in the eye may be present.
  • Subject is uncomfortable in small closed spaces (have claustrophobia) so that they would feel uncomfortable in the MRI machine.
  • Unable to lie comfortably on back for up to 1 hour
  • Under 12 years of age

There is no general exclusion for NIH employees.

Treatment and study plan

Primary outcomes

  1. The primary outcome measure is the phenotypic and genotypic characterizations of patients and family members with movement disorders.

    Time frame: 10 Years

    Characterizations to determine their eligibility for inclusion in other NIH protocols.

Secondary outcomes

  1. Identification of disease-specific biomarkers in stem cells derived from patient peripheral blood mononuclear cells or fibroblast lines

    Time frame: Study end

  2. Identification of new genes and/or peripheral blood biomarkers associated with movement disorders

    Time frame: Study end

  3. Identification of new genes and/or peripheral blood biomarkers associated with movement disorders.

    Time frame: Study end

  4. Establishment of a clinical diagnosis (when possible)

    Time frame: Study end

  5. Referral of patients and/or family members for participation in other NIH studies

    Time frame: Study end

Study contacts

Contact information is provided by the study sponsor or research team.

Debra J Ehrlich, M.D.

CONTACT

[email protected]

(301) 443-7888

Konjit Yirgashewa

CONTACT

[email protected]

(301) 594-5277

Sponsors and collaborators

Lead sponsor

National Institute of Neurological Disorders and Stroke (NINDS)

Nih

Registry information

Important dates

Study start
2001
First posted
Jul 9, 2001
Registry last updated
Jul 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.